Protecting Your Heart: Electrical Risks and Red Flags
At a Glance
In LMNA-related cardiocutaneous progeria syndrome, dangerous heart rhythm problems can develop even when heart pumping appears normal. Fainting, near-fainting, sustained palpitations, chest pain, or sudden breathlessness need urgent evaluation; regular rhythm monitoring guides ICD decisions.
Managing LMNA-related cardiocutaneous progeria syndrome (LCPS) requires a proactive approach to heart health. While earlier discussions focused on the heart valves, a critical risk in broader LMNA conditions is often “electrical.” In many people with LMNA mutations, the heart’s electrical system can begin to fail or become unstable well before the heart muscle itself shows significant weakness [1][2].
Recognizing Cardiac Emergencies
Because of the risk of sudden, dangerous heart rhythms, you must be able to recognize “red flag” symptoms that require immediate medical attention.
Call emergency services or seek immediate care if you experience:
- Syncope: Any sudden loss of consciousness or “fainting” without a clear, non-heart-related cause [3].
- Unexplained Dizziness or Presyncope: Feeling like you are about to black out, especially if accompanied by a very slow heart rate (bradycardia) [4].
- Sustained Palpitations: A feeling of your heart racing, fluttering, or pounding that does not stop quickly, especially if accompanied by chest pain or shortness of breath [5].
- Sudden Shortness of Breath or Chest Pain: Difficulty breathing that comes on rapidly, which may indicate the heart is struggling to pump effectively [6].
The Risk of Electrical Disease
In LMNA-related conditions, the mutation weakens the structural integrity of heart cells, which can disrupt the pathways that carry electrical signals. Studies on broader cohorts of people with LMNA mutations—though not specifically validated for the ultra-rare LCPS phenotype alone—show three primary types of electrical issues:
- Conduction Disease (AV Block): The electrical signal from the top of your heart to the bottom becomes delayed or blocked [1]. In broader LMNA cardiomyopathy cohorts, up to 57% develop some form of atrioventricular (AV) block [1].
- Atrial Arrhythmias: Rapid or irregular rhythms in the upper chambers, such as atrial fibrillation (AFib), are common [1]. A new diagnosis of AFib often requires evaluation for stroke prevention, including the use of blood thinners (anticoagulants).
- Malignant Ventricular Arrhythmias: These are rapid, dangerous rhythms in the lower chambers (the ventricles) that can lead to sudden cardiac death (SCD) [3]. Importantly, these can occur even if your heart’s “squeeze” (LVEF) appears normal on an ultrasound [2].
Protecting the Heart: ICDs as a Decision Support Tool
Because of the high risk of sudden death in LMNA cardiomyopathies, an Implantable Cardioverter-Defibrillator (ICD) is often considered. An ICD monitors your heart 24/7 and can deliver a life-saving shock if it detects a dangerous rhythm [7].
Deciding to implant an ICD requires shared decision-making with your electrophysiologist, weighing the benefits against potential device complications. In broader LMNA populations, clinical guidelines use specific tools to aid this discussion [5]:
- A “two-risk-factor” threshold (considering factors like male sex, LVEF <45%, Nonsustained Ventricular Tachycardia (NSVT), and non-missense mutations).
- An “LMNA risk calculator” that estimates 5-year arrhythmia risk. A risk of 10% or higher is a commonly cited threshold for ICD consideration [8].
Keep in mind that these tools were developed for LMNA cardiomyopathy and are not definitively validated rules for the specific LCPS phenotype. Your team will personalize this decision.
ICD Action Plan
If you choose to receive an ICD, establish a clear action plan with your clinic. Generally:
- If you receive a single shock but feel completely fine afterward, contact your device clinic promptly for an evaluation.
- If you receive multiple shocks, feel dizzy, experience chest pain, or remain unwell, call emergency services immediately.
Other Heart Rhythm Procedures
- Catheter Ablation: This procedure is used to “burn away” the source of an arrhythmia. While it can be useful, success varies widely depending on the specific rhythm treated and the stage of disease; for severe ventricular arrhythmias in LMNA patients, recurrence can be high [9] because scarring is often deep within the muscle [10].
- Pacemakers: If you require a device solely for a slow heart rate (conduction disease), your doctor may discuss whether an ICD-capable system is preferable to a standard pacemaker, as LMNA disease can progress and device upgrades are common [11].
Regular follow-up with an electrophysiologist is essential. They will monitor your rhythm through EKGs, Holter monitors, and potentially cardiac MRI to look for fibrosis (scarring), which is a major predictor of future electrical issues [12].
Common questions in this guide
Which symptoms mean I should seek emergency care with LCPS?
Can a dangerous rhythm happen if my heart’s pumping function is normal?
Why might an ICD be recommended for someone with LCPS?
What factors help estimate the need for an ICD in LMNA disease?
How is heart rhythm monitored in LCPS?
What should I do after my ICD delivers a shock?
Would an ICD-capable device be better than a pacemaker if I have a slow heart rate?
Get notified when new evidence is published on LMNA-related cardiocutaneous progeria syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers.
Kumar S, Baldinger SH, Gandjbakhch E, et al.
Journal of the American College of Cardiology 2016; (68(21)):2299-2307 doi:10.1016/j.jacc.2016.08.058.
PMID: 27884249 - 2
Cardiac and Neuromuscular Features of Patients With LMNA-Related Cardiomyopathy.
Peretto G, Di Resta C, Perversi J, et al.
Annals of internal medicine 2019; (171(7)):458-463 doi:10.7326/M18-2768.
PMID: 31476771 - 3
Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies.
Wahbi K, Ben Yaou R, Gandjbakhch E, et al.
Circulation 2019; (140(4)):293-302 doi:10.1161/CIRCULATIONAHA.118.039410.
PMID: 31155932 - 4
Clinical Profile, Arrhythmias, and Adverse Cardiac Outcomes in Emery-Dreifuss Muscular Dystrophies: A Systematic Review of the Literature.
Valenti AC, Albini A, Imberti JF, et al.
Biology 2022; (11(4)) doi:10.3390/biology11040530.
PMID: 35453731 - 5
Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry.
Barriales-Villa R, Ochoa JP, Larrañaga-Moreira JM, et al.
Revista espanola de cardiologia (English ed.) 2021; (74(3)):216-224 doi:10.1016/j.rec.2020.03.026.
PMID: 32616434 - 6
LMNA Cardiomyopathy: Important Considerations for the Heart Failure Clinician.
Rosario KF, Karra R, Amos K, et al.
Journal of cardiac failure 2023; (29(12)):1657-1666 doi:10.1016/j.cardfail.2023.08.016.
PMID: 37659618 - 7
Cardiolaminopathies from bench to bedside: challenges in clinical decision-making with focus on arrhythmia-related outcomes.
Boriani G, Biagini E, Ziacchi M, et al.
Nucleus (Austin, Tex.) 2018; (9(1)):442-459 doi:10.1080/19491034.2018.1506680.
PMID: 30130999 - 8
Missense and Non-Missense Lamin A/C Gene Mutations Are Similarly Associated with Major Arrhythmic Cardiac Events: A 20-Year Single-Centre Experience.
Forleo C, Carella MC, Basile P, et al.
Biomedicines 2024; (12(6)) doi:10.3390/biomedicines12061293.
PMID: 38927500 - 9
Outcomes of Ventricular Tachycardia Ablation in Cardiac Laminopathy: An Updated Systematic Review and Single-Arm Meta-Analysis.
Castrichini M, Ferreira Felix I, Karlinski Vizentin V, et al.
Journal of cardiovascular electrophysiology 2026; (37(2)):268-274 doi:10.1111/jce.70193.
PMID: 41331778 - 10
Multicenter Experience With Catheter Ablation for Ventricular Tachycardia in Lamin A/C Cardiomyopathy.
Kumar S, Androulakis AF, Sellal JM, et al.
Circulation. Arrhythmia and electrophysiology 2016; (9(8)).
PMID: 27506821 - 11
Timing of pacemaker and ICD implantation in LMNA mutation carriers.
Ollila LH, Nikus K, Parikka H, et al.
Open heart 2021; (8(1)) doi:10.1136/openhrt-2021-001622.
PMID: 33893211 - 12
Late gadolinium enhancement role in arrhythmic risk stratification of patients with LMNA cardiomyopathy: results from a long-term follow-up multicentre study.
Peretto G, Barison A, Forleo C, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2020; (22(12)):1864-1872 doi:10.1093/europace/euaa171.
PMID: 32995851
This page is for informational purposes only and does not replace medical advice. Ask your cardiologist or electrophysiologist about your symptoms, rhythm monitoring, and whether an ICD or other device is appropriate for you.